BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Boehringer Ingelheim
Citi
QuintilesIMS
Accenture
Merck
US Department of Justice
Julphar
UBS
McKesson

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,087,383

« Back to Dashboard

Which drugs does patent 6,087,383 protect, and when does it expire?

Patent 6,087,383 protects REYATAZ and EVOTAZ and is included in three NDAs.

Protection for REYATAZ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty patent family members in thirty-eight countries.
Summary for Patent: 6,087,383
Title: Bisulfate salt of HIV protease inhibitor
Abstract:The present invention provides the crystalline bisulfate salt of the formula ##STR1## which is found to have unexpectedly high solubility/dissolution rate and oral bioavailability relative to the free base form of this azapeptide HIV protease inhibitor compound.
Inventor(s): Singh; Janak (Lawrenceville, NJ), Pudipeddi; Madhusudhan (Plainsboro, NJ), Lindrud; Mark D. (Basking Ridge, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:09/217,538
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form;

Drugs Protected by US Patent 6,087,383

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-001 Jun 20, 2003 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-002 Jun 20, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-003 Jun 20, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-004 Oct 16, 2006 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bristol Myers Squibb REYATAZ atazanavir sulfate POWDER;ORAL 206352-001 Jun 2, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Bristol-myers Squibb EVOTAZ atazanavir sulfate; cobicistat TABLET;ORAL 206353-001 Jan 29, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,087,383

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland 342019 ➤ Subscribe
Peru 01852000 ➤ Subscribe
New Zealand 504417 ➤ Subscribe
Norway 315605 ➤ Subscribe
Norway 20003692 ➤ Subscribe
Malaysia 114838 ➤ Subscribe
Latvia 12522 ➤ Subscribe
Lithuania 4780 ➤ Subscribe
Lithuania 2000067 ➤ Subscribe
South Korea 100559283 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Deloitte
Accenture
Fish and Richardson
Express Scripts
Covington
Merck
Cipla
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot